Concepedia

K. T. Flaherty

KT

Statistics

Publications

20

Citations

817

H-Index

16

Active since

2004

Affiliations

Bayer (United States)(Current)

University of Pennsylvania

Memorial Sloan Kettering Cancer Center

Massachusetts General Hospital

Adaptive Biotechnologies (United States)

K. T. Flaherty is an author at Bayer (United States) specializing in medicine, pharmacology, and cancer pharmacology.

Publications per year

2004–2024

20

Publications

20

Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)

Mark J. Ratain, K. T. Flaherty, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 107 citations

, , +17

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2005 · 97 citations

, , +16

Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)

Jeffrey A. Sosman, K. T. Flaherty, Michael B. Atkins et al. · Journal of Clinical Oncology · 2008 · 83 citations

, , +16

Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.

K. T. Flaherty, S. J. Lee, Lynn M. Schuchter et al. · Journal of Clinical Oncology · 2010 · 60 citations

, , +15

Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma

K. T. Flaherty, Marcia S. Brose, L. Schuchter et al. · Journal of Clinical Oncology · 2004 · 51 citations

, , +17

1–5 of 20